1. De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747.
2. Wang H. Practical updates in clinical antiviral resistance testing. J Clin Microbiol. 2024 Aug 14;62(8):e0072823.
3. Chou S. Antiviral susceptibility testing. In: Bamford D, Zuckerman M, editors. Encyclopaedia of Virology. 4th ed. Amsterdam: Academic Press; 2021. p. 540–546.
4. van der MT, Claas ECJ. Phenotypic and genotypic antiviral susceptibility testing. In: Loeffelholz M, Hodinka RL, Young SA, Pinsky BA, editors. Clinical virology manual. 5th ed. Washington
(DC): ASM Press; 2016. p. 201–228.
5. Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24(2):413–437.
6. Tardif KD, Jorgensen S, Langer J, Prichard M, Schlaberg R. Simultaneous titration and phenotypic antiviral drug susceptibility testing for herpes simplex virus 1 and 2. J Clin Virol.
2014;61(3):382–386.
7. Safrin S, Palacios E, Leahy BJ. Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex
virus isolates. Antimicrob Agents Chemother. 1996;40(4):1017–1019.
8. World Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: neuraminidase inhibitor (NAI) [Internet]. Geneva: WHO; [27 Ekim 2025].
Webadresi:https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza/neuraminidase-inhibitor
9. Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and viro-
logic outcomes in uncomplicated influenza. J Infect Dis. 2020;221(3):346–355.
10. Erasmus Smit, Antiviral resistance testing. Curr Opin Infect Dis 2014, 27:566–572.
11. Gibson RM, Meyer AM, Winner D, et al. Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and
maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother [internet] 2014; 58:2167–2185.
12. Dudley D, Chin E, Bimber B. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One [internet]. 2012; 7 (5).
13. Gianella S, Delport W, Pacold ME, et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of
multiple viral variants? Society 2011;85:8359–8367.
14. Stekler JD, Ellis GM, Carlsson J, et al. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One [internet] 2011; 6:e28952.
15. Gianella S, Richman D. Minority variants of drug-resistant HIV. J Infect Dis [internet]. 2010; 202.
16. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV
Med [internet]. 2014; 15:1–85.
17. Asboe D, Aitken C, Boffito M, et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13:1–44.
18. James SH, Prichard MN. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance. Curr Opin Virol. 2014;8:54–61.
19. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26(1):29–37.
20. Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and
DNA polymerase genes of herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2016;71(1):6–16.
21. Safrin S, Elbeik T, Phan L, Robinson D, Rush J, Elbaggari A, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex
virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1994;38(6):1246–1250.
22. Casto AM, Stout SC, Selvarangan R, Freeman AF, Newell BD, Stahl ED, et al. Evaluation of genotypic antiviral resistance testing as an alternative to phenotypic testing in a patient with DOCK8
deficiency and severe HSV-1 disease. J Infect Dis. 2020;221(12):2035–2042.
23. Afshar B, Bibby DF, Piorkowska R, Ohemeng-Kumi N, Snoeck R, Andrei G, et al. A European multi-centre external quality assessment study on phenotypic and genotypic methods used for
herpes simplex virus drug resistance testing. J Clin Virol. 2017;96:89–93.
24. Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol.
2004;42(1):242–249.
25. Duan R, de Vries RD, Osterhaus ADME, Remeijer L, Verjans GMGM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis. 2008;198(5):659–663.
26. Chou S. Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. Antiviral Res. 2020;176:104711.
27. Kleiboeker S, Nutt J, Schindel B, Dannehl J, Hester J. Cytomegalovirus antiviral resistance: characterization of results from clinical specimens. Transpl Infect Dis. 2014;16(4):561–567.
28. Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus
infection in transplant recipients. J Infect Dis. 2024;229(3):413–421.
29. Douglas CM, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M, et al. Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell
transplant recipients. J Infect Dis. 2020;221(7):1117–1126.
30. Stanford University. HIV drug resistance database [Internet]. Stanford (CA): Stanford University; (27 Ekim 2025’de ziyaret edildi). Web adresi: https://hivdb.stanford.edu/
31. Mohan T, Nguyen HT, Kniss K, Mishin VP, Merced-Morales AA, Laplante J, et al. Cluster of oseltamivir-resistant and hemagglutinin antigenically drifted influenza A(H1N1)pdm09 viruses,
Texas, USA, January 2020. Emerg Infect Dis. 2021;27(7):1953–1957.
32. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for ma-
nagement. Hepatology. 2007;46(1):254–265.
33. Pawlotsky J-M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70–86.
34. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ
transplantation. Transplantation. 2018;102(6):900–931.
35. El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–2636.
36. Streck NT, Espy MJ, Ferber MJ, Klee EW, Razonable RR, Gonzalez D, et al. Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus.
J Clin Microbiol. 2023;61(10):e00429-23.
37. Chou S, Ercolani RJ, Sahoo MK, Lefterova MI, Strasfeld LM, Pinsky BA. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Anti-
microb Agents Chemother. 2014;58(8):4697–4702.
38. Piret J, Schibler M, Pham VD, Hantz S, Giannotti F, Masouridi-Levrat S, et al. Compartmentalization of a multidrug-resistant cytomegalovirus UL54 mutant in a stem cell transplant recipient
with encephalitis. J Infect Dis. 2019;220(8):1302–1306.
39. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. Department of Health and Human
Services; [27 Ekim 2025’de ziyaret edildi]. Web adresi: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
40. Shafer RW, Boivin G, Chou S. Mechanisms of resistance to antiviral agents. In: Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW, editors. Manual of clinical
microbiology. 12th ed. Vol 2. Washington (DC): ASM Press; 2019. p. 1962–1984.
41. Muccini C, Galli L, Sampaolo M, Gianotti N, Castagna A, Canetti D. Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with
HIV. J Antimicrob Chemother. 2023;78(5):1314–1315.
42. McGee KS, Okeke NL, Hurt CB, McKellar MS. Canary in the coal mine? Transmitted mutations conferring resistance to all integrase strand transfer inhibitors in a treatment-naive patient.
Open Forum Infect Dis. 2018;5(12):ofy294.
43. Bonifacio MA, Genchi C, Lagioia A, Talamo V, Volpe A, Mariggiò MA. Analytical assessment of the Vela Diagnostics NGS assay for HIV genotyping and resistance testing: the Apulian expe-
rience. Int J Mol Sci. 2022;23(5):2727.
44. Tzou PL, Ariyaratne P, Varghese V, Lee C, Rakhmanaliev E, Villy C, et al. Comparison of an in vitro diagnostic next-generation sequencing assay with Sanger sequencing for HIV-1 genotypic
resistance testing. J Clin Microbiol. 2018;56(7):e00105-18.
45. May S, Adamska E, Tang J. Evaluation of Vela Diagnostics HIV-1 genotyping assay on an automated next generation sequencing platform. J Clin Virol. 2020;127:104376.
46. Dalmat RR, Makhsous N, Pepper GG, Magaret A, Jerome KR, Wald A, Greninger AL. Limited marginal utility of deep sequencing for HIV drug resistance testing in the age of integrase
inhibitors. J Clin Microbiol. 2018;56(12):e01443-18.
47. Stella-Ascariz N, Arribas JR, Paredes R, Li JZ. The role of HIV-1 drug-resistant minority variants in treatment failure. J Infect Dis. 2017;216(Suppl 9):S847–S850.
48. Curanovic D, Martens SK, Rodriguez MA, Hammill HA, Petropoulos CJ, Walworth CM. HIV-1 DNA testing in viremic patients identifies more drug resistance than HIV-1 RNA testing. Open
Forum Infect Dis. 2023;10(5):ofad146.
49. Chu C, Armenia D, Walworth C, Santoro MM, Shafer RW. Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells. Clin Microbiol Rev. 2022;35(2):e00052-22.
50. Harding J, Bernasconi C, Williams S, Wildum S, Kinoshita M, Uehara T, et al. Investigating the transmission of baloxavir-resistant influenza viruses from treated index patients to untreated
household contacts in the BLOCKSTONE study. Influenza Other Respir Viruses. 2023;17(5):e13079.
51. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepa-
tology. 2018;67(4):1560–1599.
52. Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for hepatitis B virus. Nucleic Acids Res. 2013;41(D1):D566–D570.
53. Rhee S-Y, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel B, et al. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation dis-
covery. Antiviral Res. 2010;88(3):269–275.
54. Bhattacharya D, Aronsohn A, Price J, Lo Re V, Heald J, Demisashi G, et al. Hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases–Infectious Diseases Society
of America recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023.
55. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194.
56. Singer JB, Thomson EC, McLauchlan J, Hughes J, Gifford RJ. GLUE: a flexible software system for virus sequence data. BMC Bioinformatics. 2018;19(1):532.